What a Peptide Certificate of Analysis Shows

What does a COA actually show?

You read a COA as a batch report. A lab ties each result to one lot number, so results for one batch say nothing about the next batch. The paper can support identity, purity, quantity, sterility, or endotoxin claims only when each test appears on the page (Rite Aid COA guide).

Identity testing, often mass spectrometry, checks that the measured weight matches the expected peptide. Purity testing, often HPLC, separates the sample to estimate how much is the intended peptide. Quantity states how much material the lab measured. One purity number cannot answer every quality question.

Why doesn't high purity mean sterile?

Chemical purity and sterility belong to different testing worlds. USP compounding rules state sterile work differs from nonsterile work primarily because it requires a test for sterility, plus cleaner rooms and trained aseptic technique (USP <797>). The same chapter warns that water-based injections given into veins or around the spinal cord carry the highest risk when sterility fails.

USP keeps separate tests for germs and bacterial toxins. Chapter <71> covers sterility tests (USP <71> Sterility Tests). Chapter <85> covers bacterial endotoxins, which are residues from bacteria, and uses LAL, a reagent made from horseshoe crab blood, to find or measure those toxins (USP <85> Endotoxins Test). A COA that lists only HPLC and mass spectrometry gives you no information about either result.

Does a COA or pharmacy label mean it is proven and approved?

A COA serves as a starting paper for legal compounding. For 503B outsourcing facilities, FDA requires bulk ingredients to arrive with a valid COA, to come from an FDA-registered maker, and to meet a USP standard when one exists (FDA 503B rules). Those papers show sourcing met a baseline. They do not show a treatment works for your goal.

The pharmacy path also changes who oversees your prescription. A 503A pharmacy makes a drug for one named patient under state board rules. A 503B facility makes larger runs under federal rules (Newtropin 503A vs 503B).

Advisory votes have not changed approval status. In 2026 an FDA advisory committee gave favorable views on BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, but those views do not approve a drug. None of the six is FDA-approved or listed in 21 CFR 216.23, the federal compounding list, as of July 26, 2026 (Dr. Sobo review). If you want help weighing whether a peptide treatment fits your skin, weight, or recovery goals, your answers through the quiz let the HOD clinical team assess you for a personal plan.